Tesamorelin Guide: GHRH Analog and Visceral Fat Biology

By Justin Cartier

See how this fits the wider landscape of growth-hormone and muscle research peptides.

Tesamorelin is a GHRH analog, which is a stand-in for growth hormone-releasing hormone. It’s also the only one of its kind that carries FDA approval for changing body composition. In two big Phase 3 trials it cut deep belly fat by 15 to 18 percent over 26 weeks, and it did that without touching the fat under the skin or eating into muscle mass. That fat-targeting is the whole reason it stands apart from plain growth hormone.

This article is for research and educational use only. Tesamorelin is treated here as a research compound, not approved for human use, and nothing on this page is medical advice.

The way it’s built explains why it lasts. Natural GHRH gets chewed up by the DPP-4 enzyme in under ten minutes. Tesamorelin wears a small chemical cap on one end that blocks that breakdown, and the cap doesn’t change how the molecule grips the GHRH receptor, so it survives about 26 minutes instead. That’s still short, but it’s long enough to keep growth hormone coming out in natural pulses. Plain injected growth hormone does the opposite, flooding you with a flat, too-high level. And the pulse pattern really matters here, because it’s the rhythm, not just the raw total, that drives the effects on IGF-1 and on excess fat.

This guide walks through how tesamorelin works at the GHRH receptor, what the published trials show on belly fat, IGF-1, and blood lipids, how it stacks up against sermorelin and ipamorelin, why it gets used off-label outside the approved group, and what to look for when sourcing material.

What does tesamorelin do for you?

In plain terms, it nudges your own pituitary to release more growth hormone, and over months of steady use that translates into real, measurable drops in deep abdominal fat. Put simply, tesamorelin therapy goes after fat accumulation deep in the belly. González-Sales and colleagues, in Clinical Pharmacokinetics, describe it as a synthetic version of growth hormone-releasing factor with a much longer half-life than the native hormone, which is exactly what lets it work as a once-daily shot instead of the constant infusion natural GHRH would need.

It also holds a unique regulatory spot. Grunfeld, writing in Nature Reviews Drug Discovery, notes the FDA cleared tesamorelin in November 2010 to cut excess abdominal fat in people with HIV who had developed fat redistribution. No other GHRH analogue has an approved body-composition use, so this one is still the benchmark for the class.

Mechanism of action: pulsatile GH and downstream IGF-1

The whole thing runs through the GHRH receptor sitting on cells in the front of the pituitary. Stanley and colleagues, in the Journal of Clinical Endocrinology & Metabolism, showed that tesamorelin bumps up both the baseline and the pulsing release of GH, and crucially it keeps that natural pulse pattern rather than flattening it into a constant high. The GH that gets released then circulates and tells the liver to make IGF-1 over the next 12 to 24 hours.

So why does it hit belly fat specifically? It comes down to where the receptors sit. Fat cells packed deep in the abdomen carry more GH receptors than the fat just under your skin. That means the fat-burning signal lands harder on the deep stores, which is the biological reason the effect is so selective: the surface fat mostly stays put while the deep depots shrink.

Visceral fat reduction in the approved group

The Phase 3 trials are the strongest evidence we have. Falutz and colleagues, in the Journal of Acquired Immune Deficiency Syndromes, reported that tesamorelin trimmed deep abdominal fat by roughly 18 percent over 26 weeks and eased the distress patients felt about their body image.^[1] Spooner, reviewing the data in Annals of Pharmacotherapy, confirmed it clearly shrank waist size and the deep fat depot without messing up blood sugar control.^[3]

The standard treatment window is 26 weeks. The fat loss tends to plateau around month 6, and here’s the catch: you have to keep dosing to hold onto it. Stop, and the deep fat drifts back toward where it started over the following 6 to 12 months.

Why do bodybuilders take tesamorelin?

Bodybuilders reach for it off-label because that belly-selective fat burning is genuinely appealing for stage-prep and cutting, when overall body fat is already low but the stubborn abdominal pad won’t budge. The pulsing GH release also delivers a modest bump in lean mass through IGF-1, riding on the back of the fat-burning effect. But be clear about what this is: off-label, unmonitored, and often at doses above what’s approved. The approved Egrifta dose is 2 mg a day, while some bodybuilding protocols push to 4 mg or higher. It’s also on the World Anti-Doping Agency banned list, so any use in competitive sport is a sanctioning risk.

Is tesamorelin the same as Ozempic?

No, and they’re not even close. Tesamorelin is a GHRH analogue that stimulates growth hormone release, while Ozempic (semaglutide) is a GLP-1 receptor agonist that drives weight loss by curbing appetite and slowing the stomach. The mechanisms sit in completely different worlds. Tesamorelin works on the GHRH receptor in the pituitary, whereas semaglutide works on the GLP-1 receptor in the pancreas and the brain’s appetite centers. Tesamorelin selectively strips deep abdominal fat, while semaglutide pulls down total body weight across the board. One is a daily shot, the other is once weekly. And they’re approved for entirely different things, fat redistribution in one case versus diabetes and obesity in the other.

Tesamorelin vs sermorelin and ipamorelin

All three poke at the GH axis, just at different spots. Tesamorelin is a GHRH analogue (the 1-44 form) with a longer half-life than the native hormone, and it’s the one with FDA approval. Sermorelin is also a GHRH analogue, but the shorter 1-29 form with a briefer half-life; it was once approved for pediatric GH deficiency and is now research-only. Ipamorelin is a different animal altogether, a secretagogue that works on the ghrelin receptor rather than the GHRH receptor, so it triggers a pulse instead of lifting the baseline.

Of the three, tesamorelin produces the strongest belly-fat-specific effect because it sustains the most GH exposure over time. Sermorelin is gentler and fits age-related GH decline better than any sharp body-composition goal. Ipamorelin really shines when it’s stacked with a GHRH analogue, often CJC-1295, rather than run solo for fat loss.

Dosage, storage, and administration

The approved Egrifta dose is 2 mg by subcutaneous injection once a day, and research and off-label use have ranged from 1 to 4 mg daily. It ships as a freeze-dried powder that you reconstitute in sterile water, and once mixed it keeps in the fridge for up to 28 days. Rotate your injection sites to keep irritation down; the stomach area and outer thigh are the usual spots.

Who should not take tesamorelin?

The Egrifta label spells out a handful of hard contraindications. Pregnancy is out, since the safety data isn’t there and raised maternal GH could affect the fetus. Active cancer is out too, because bumping up GH and IGF-1 might speed certain tumors along. It’s also off the table for pituitary disorders, hypopituitarism, or hypothalamic disease. Same goes for acute critical illness after major surgery or trauma. And it’s out for anyone allergic to tesamorelin or to mannitol, the filler in Egrifta. Beyond those, diabetes and a history of heart disease are softer cautions rather than flat bans, mostly because GH pushes back against insulin.

Timing of effects: what to expect month by month

The hormonal side kicks in fast. A single shot lifts plasma GH within 30 to 60 minutes and raises IGF-1 within 12 to 24 hours. The body-composition side is a slower burn. Most people see no real change in the first 4 weeks, a modest waist reduction by week 8, a more obvious drop in deep fat on imaging by week 12, and the full 15 to 18 percent by week 26. The impact of tesamorelin on muscle mass is smaller and harder to pin down, usually a few percent over the same stretch. And as noted, stop at any point and the deep fat creeps back over 6 to 12 months.

Side effects of tesamorelin

The most common complaint by far is injection-site trouble, hitting around 25 percent of patients as redness, swelling, or mild pain where the needle goes in. Joint and muscle pain show up in maybe 5 to 10 percent. Swelling in the limbs and a pins-and-needles feeling are on record but less common. GH pushes against insulin, so blood sugar can tick up for a while, though in the trial population that never turned into meaningful high blood sugar. On the whole, the safety of tesamorelin is well characterized precisely because it went through approved clinical use.

Drug interactions

Because tesamorelin can move blood sugar, insulin and oral diabetes drugs may need adjusting in diabetic users. GH can also shift how the liver processes certain drugs, so some CYP3A4 substrates may clear differently. Corticosteroids taken alongside it can blunt the fat-burning effect. On the plus side, it has no known clash with antiretroviral therapy in people with HIV.

Legal status

Tesamorelin (Egrifta) is FDA-approved in the United States for HIV-associated fat redistribution. Health Canada hasn’t approved it as a finished drug. Research-grade material is legal in Canada and the United States under research-use-only labelling. And again, it’s on the World Anti-Doping Agency banned list.

Research-grade tesamorelin is legal to buy in Canada and the United States under research-use-only labelling. Our guide to Canada’s peptide legal framework covers those rules and the supplier criteria that go with them.

Sourcing for research

Tesamorelin is a 44-amino-acid GHRH copy with a protective end-cap, and its expected molecular weight sits near 5,196 Da. An unverified vial can quietly miss any of that. If the powder is a shortened sequence, an un-capped copy that the DPP-4 enzyme shreds in minutes, or a different peptide entirely, your GH and IGF-1 readings drift for reasons that have nothing to do with your question. Then weeks of a 26-week protocol are gone on a result nobody can repeat. That is why identity comes first. Get a Certificate of Analysis an outside lab ran on that exact lot, with HPLC purity and mass spectrometry confirming that roughly 5,196 Da mass, before any animal or cell work starts. For in-vivo or cell-culture use, add endotoxin and sterility testing to guard the experiment.

Reviv Peptides supplies research-grade tesamorelin with third-party COA and HPLC purity confirmation. View the Tesamorelin product page.

Tesamorelin questions

What does tesamorelin do for you?

It drives pulsing release of your own growth hormone, raises IGF-1, and cuts deep abdominal fat by roughly 15 to 18 percent over 26 weeks of daily use. It’s FDA-approved for HIV-associated fat redistribution.

Who should not take tesamorelin?

Steer clear with pregnancy, active cancer, pituitary disorders, acute critical illness, or an allergy to tesamorelin or mannitol. Diabetes and heart disease are softer cautions rather than outright bans.

Why do bodybuilders take tesamorelin?

For belly-selective fat burning during cutting and stage-prep. It’s on the WADA banned list, so competitive athletic use is a sanctioning risk, and any such use is off-label.

Is tesamorelin the same as Ozempic?

No. Tesamorelin is a GHRH analogue that stimulates GH release, while Ozempic (semaglutide) is a GLP-1 agonist that drives weight loss through appetite suppression. The mechanisms and effects are completely different.

What are the potential side effects of tesamorelin?

Mostly injection-site reactions (around 25 percent), joint pain (5 to 10 percent), muscle pain, limb swelling, and a temporary rise in blood sugar. It doesn’t usually cause meaningful high blood sugar in people without diabetes.

Key data point: in the pivotal Egrifta Phase 3 program, Falutz and colleagues (2010, Journal of Acquired Immune Deficiency Syndromes) reported tesamorelin at 2 mg a day cut deep abdominal fat by about 15 percent versus roughly 2 percent on placebo at 26 weeks, measured on CT imaging, alongside a triglyceride drop of around 50 mg/dL and no meaningful hit to surface fat or lean body mass.^[1]

Summary

Tesamorelin is the only GHRH analogue approved as a finished drug for a body-composition use. It drives pulsing growth hormone release through the pituitary GHRH receptor, lifts IGF-1 over the 12 to 24 hours after each dose, and selectively trims deep abdominal fat by 15 to 18 percent over 26 weeks. Its fat-selectivity, its track record from real clinical use, and its well-mapped pharmacology make it the benchmark of the class. Off-label use in bodybuilding and sport carries WADA-banned-list risk. Research-grade material is legal in Canada and the United States under research-use-only labelling.

Sources

Sources: [1] Tesamorelin reduces visceral fat in HIV lipodystrophy (Phase 3 RCT), PubMed/NIH. [2] Tesamorelin augments basal and pulsatile GH secretion, PubMed/NIH. [3] Tesamorelin decreases waist circumference and visceral fat (review), PubMed/NIH. [4] Tesamorelin overview and FDA approval (2010), PubMed/NIH. [5] Population pharmacokinetics of tesamorelin, PubMed/NIH.